MCID: HYP070
MIFTS: 42

Hyperpituitarism

Categories: Endocrine diseases

Aliases & Classifications for Hyperpituitarism

MalaCards integrated aliases for Hyperpituitarism:

Name: Hyperpituitarism 12 45 15 17 74

Classifications:



External Ids:

Disease Ontology 12 DOID:2444
MeSH 45 D006964
SNOMED-CT 69 10649000
UMLS 74 C0020506

Summaries for Hyperpituitarism

MalaCards based summary : Hyperpituitarism is related to hyperthyroidism and hypopituitarism. An important gene associated with Hyperpituitarism is IGF1 (Insulin Like Growth Factor 1), and among its related pathways/superpathways are TGF-Beta Pathway and PI3K-Akt signaling pathway. The drugs Dopamine and Risperidone have been mentioned in the context of this disorder. Affiliated tissues include pituitary, bone and brain, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 77 Hyperpituitarism is a condition due to the primary hypersecretion of pituitary hormones; it typically... more...

Related Diseases for Hyperpituitarism

Diseases related to Hyperpituitarism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 140)
# Related Disease Score Top Affiliating Genes
1 hyperthyroidism 29.7 GH1 INS PRL SST TRH
2 hypopituitarism 29.2 GH1 GHRH IGF1 INS POMC PRL
3 galactorrhea 10.4 IGF1 PRL
4 glucagonoma 10.3 GHRH SST
5 prolactin producing pituitary tumor 10.3 PRL SST
6 mammographic density 10.3 IGF1 PRL
7 pancreatic cholera 10.3 GHRH SST
8 bronchus adenoma 10.3 POMC SST
9 bronchial adenomas/carcinoids childhood 10.3 POMC SST
10 generalized resistance to thyroid hormone 10.3 PRL TRH
11 zollinger-ellison syndrome 10.3 GHRH SST
12 spinocerebellar degeneration 10.3 PRL SST
13 fasting hypoglycemia 10.3 IGF1 POMC
14 central precocious puberty 10.3 GH1 IGF1
15 marasmus 10.3 GH1 IGF1
16 fibrous dysplasia/mccune-albright syndrome 10.3 GH1 PRL
17 secondary adrenal insufficiency 10.3 IGF1 INS
18 acth-secreting pituitary adenoma 10.3 POMC PRL
19 suprasellar meningioma 10.3 POMC TRH
20 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.3 IGF1 INS
21 cone-rod dystrophy 12 10.3 GH1 IGF1
22 duodenal somatostatinoma 10.2 INS SST
23 somatostatinoma 10.2 INS SST
24 postgastrectomy syndrome 10.2 INS SST
25 abducens nerve disease 10.2 POMC PRL
26 noma 10.2 INS POMC
27 insulinomatosis and diabetes mellitus 10.2 INS SST
28 donohue syndrome 10.2 IGF1 INS
29 lymphocytic hypophysitis 10.2 GH1 POMC
30 diabetes insipidus, neurohypophyseal 10.2 POMC PRL
31 carcinoid syndrome 10.2 GHRH IGF1 SST
32 fibromyalgia 10.2 IGF1 PRL
33 dumping syndrome 10.2 INS SST
34 hypoadrenalism 10.2 GH1 POMC
35 traumatic brain injury 10.2 GH1 IGF1
36 ectopic cushing syndrome 10.2 POMC SST
37 graves' disease 10.2
38 scleredema adultorum 10.2 INS POMC
39 functional gastric disease 10.2 INS SST
40 acromesomelic dysplasia, maroteaux type 10.2 GHR IGF1
41 acidophil adenoma 10.2 IGF1 POMC SST
42 pancreatic cystadenoma 10.2 INS SST
43 tetrahydrobiopterin deficiency 10.2 GH1 PRL
44 graves disease 1 10.2 INS TRH
45 fetal macrosomia 10.2 IGF1 INS
46 gastrinoma 10.2 INS SST
47 premenstrual tension 10.2 POMC PRL
48 mucinoses 10.2 INS POMC
49 growth hormone deficiency 10.1 GH1 GHRH IGF1
50 chiasmal syndrome 10.1 POMC PRL SST

Graphical network of the top 20 diseases related to Hyperpituitarism:



Diseases related to Hyperpituitarism

Symptoms & Phenotypes for Hyperpituitarism

GenomeRNAi Phenotypes related to Hyperpituitarism according to GeneCards Suite gene sharing:

27 (show all 24)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.8 GH1 POMC SSTR2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.8 POMC
3 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.8 GH1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.8 POMC
5 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.8 GH1 SSTR2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.8 SSTR2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.8 GH1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.8 SSTR2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.8 SSTR2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.8 GH1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.8 SSTR2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.8 SSTR2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.8 GH1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.8 SSTR2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.8 GH1 SSTR2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.8 POMC
17 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.8 POMC
18 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.8 SSTR2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.8 GH1 SSTR2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.8 SSTR2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.8 SSTR2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.8 POMC
23 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.8 POMC SSTR2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-96 9.8 GH1

MGI Mouse Phenotypes related to Hyperpituitarism:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.97 AIP GHR GHRH IGF1 INS POMC
2 homeostasis/metabolism MP:0005376 9.96 AIP GHR GHRH IGF1 INS POMC
3 growth/size/body region MP:0005378 9.92 AIP GHR GHRH IGF1 INS POMC
4 integument MP:0010771 9.63 AIP GHR IGF1 INS POMC PRL
5 liver/biliary system MP:0005370 9.43 AIP GHR GHRH INS POMC PRL
6 nervous system MP:0003631 9.28 GHR GHRH IGF1 INS POMC PRL

Drugs & Therapeutics for Hyperpituitarism

Drugs for Hyperpituitarism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 183)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 62-31-7, 51-61-6 681
2
Risperidone Approved, Investigational Phase 4,Phase 3,Not Applicable 106266-06-2 5073
3
Aripiprazole Approved, Investigational Phase 4,Not Applicable 129722-12-9 60795
4
lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 108736-35-2
5
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 83150-76-9 6400441 383414
6
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
7
Pasireotide Approved Phase 4,Phase 3,Phase 2,Phase 1 396091-73-9 9941444
8
Mecasermin Approved, Investigational Phase 4,Phase 3,Not Applicable 68562-41-4
9
Quinagolide Approved, Investigational Phase 4 87056-78-8, 97805-50-0 105105
10
Cabergoline Approved Phase 4,Phase 3,Phase 2 81409-90-7 54746
11
Liraglutide Approved Phase 4 204656-20-2 44147092
12
Metformin Approved Phase 4 657-24-9 14219 4091
13
Zinc Approved, Investigational Phase 4 7440-66-6 32051
14
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
15
Polyestradiol phosphate Approved Phase 4 28014-46-2
16
Lactitol Investigational Phase 4,Phase 3,Phase 1 585-86-4, 585-88-6 493591
17 Dopamine Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
18 Antidepressive Agents Phase 4,Not Applicable
19 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
20 Dopamine agonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
21 Dopamine D2 Receptor Antagonists Phase 4,Not Applicable
22 Serotonin 5-HT1 Receptor Agonists Phase 4,Not Applicable
23 Serotonin Receptor Agonists Phase 4,Not Applicable
24 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
25 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Serotonin Agents Phase 4,Phase 3,Not Applicable
27 Serotonin Antagonists Phase 4,Phase 3,Not Applicable
28 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Not Applicable
29 Serotonin 5-HT2 Receptor Antagonists Phase 4,Not Applicable
30 Paliperidone Palmitate Phase 4
31 Dopamine Antagonists Phase 4,Phase 3,Not Applicable
32 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Not Applicable
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Mitogens Phase 4,Phase 3,Phase 2,Not Applicable
35 Angiopeptin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Not Applicable
39 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 insulin Phase 4,Phase 3,Phase 2,Not Applicable
41 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Antiparkinson Agents Phase 4,Phase 3,Phase 1,Phase 2
43 Incretins Phase 4,Not Applicable
44 Liver Extracts Phase 4
45 Cardiotonic Agents Phase 4,Phase 1,Phase 2
46 Protective Agents Phase 4,Phase 1,Phase 2
47 Autonomic Agents Phase 4,Phase 2,Phase 1
48 Sympathomimetics Phase 4,Phase 1,Phase 2
49 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1
50 Hypoglycemic Agents Phase 4,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 214)
# Name Status NCT ID Phase Drugs
1 A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Unknown status NCT01742390 Phase 4 Aripiprazole;risperidone or paliperidone
2 Pasireotide LAR and Pegvisomant Study in Acromegaly Unknown status NCT02668172 Phase 4 Pasireotide LAR 60 mg;Pegvisomant
3 Effects of Sandostatin LAR® in Acromegaly Unknown status NCT01424241 Phase 4 Sandostatin LAR
4 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
5 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status NCT00552851 Phase 4 pegvisomant
6 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
7 Aripiprazole and Prolactin Study Completed NCT01085383 Phase 4 Aripiprazole
8 Endometriosis Patients Undergoing Quinagolide Treatment Completed NCT00625950 Phase 4
9 Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target Completed NCT01618513 Phase 4 Sandostatin® LAR
10 Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Completed NCT01278342 Phase 4 Sandostatin LAR;pegvisomant;cabergoline
11 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
12 Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects Completed NCT00701363 Phase 4 Lanreotide Autogel 120 mg
13 Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Completed NCT00642720 Phase 4 Pegvisomant
14 Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly Completed NCT00627796 Phase 4 Lanreotide-Autogel 120 mg
15 Acute Application of Pegvisomant and Octreotide in Acromegaly Completed NCT00595140 Phase 4 pegvisomant;combination with somatostatin analogue octreotide;combination with dopamine agonist cabergoline
16 Ultrasound Guided Octreotide LAR Injection in Acromegaly Completed NCT00552071 Phase 4 Octreotide LAR 30 MG Injection
17 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
18 Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly Completed NCT00461149 Phase 4 Octreotide-LAR
19 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
20 Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR Completed NCT00216398 Phase 4 Lanreotide (Autogel formulation)
21 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
22 Canadian Pegvisomant Compassionate Study In Acromegalic Patients Completed NCT00151437 Phase 4 Pegvisomant treatment
23 Somatuline Autogel: Acromegaly Self/Partner Injection Study Completed NCT00149188 Phase 4 Lanreotide (Autogel formulation)
24 Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction Completed NCT00145405 Phase 4 Lanreotide Autogel and Octreotide LAR
25 A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly Completed NCT00068042 Phase 4 Pegvisomant;Sandostatin LAR
26 Pegvisomant And Sandostatin LAR Combination Study Completed NCT00068029 Phase 4 Pegvisomant/ Sandostatin LAR;Sandostatin LAR;Pegvisomant
27 Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues Recruiting NCT02427295 Phase 4 Sandostatin (Octreotide Acetate)
28 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
29 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Terminated NCT01861717 Phase 4 lanreotide
30 The Luveris In Vitro Fertilization Trial Terminated NCT00889512 Phase 4 Luveris fixed dose;Luveris increasing dose
31 Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas Terminated NCT00242541 Phase 4 Octreotide acetate
32 Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine Unknown status NCT00315081 Phase 3 Bromocriptin
33 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Completed NCT01374906 Phase 3 pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
34 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
35 Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia Completed NCT00799383 Phase 3 Calcium and Vitamin D
36 Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
37 Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly Completed NCT02493517 Phase 3 Lanreotide Autogel®;Lanreotide Acetate
38 Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues Completed NCT02354508 Phase 3 Pasireotide LAR
39 Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly Completed NCT01412424 Phase 3 Octreotide capsules
40 Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly Completed NCT01137682 Phase 3 Pasireotide;octreotide LAR 30mg;lanreotide ATG 120mg
41 Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma Completed NCT00690898 Phase 3 Lanreotide autogel 120 mg
42 Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients Completed NCT00635765 Phase 3 C2L-OCT-01 PR 30 mg
43 Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients Completed NCT00616551 Phase 3 C2L-OCT-01 PR, 30 mg;Octreotide acetate prolonged release, 30 mg
44 Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly Completed NCT00600886 Phase 3 Pasireotide;Octreotide
45 Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly Completed NCT00499993 Phase 3 lanreotide (Autogel formulation), duration of treatment 46-48 weeks
46 Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel Completed NCT00447499 Phase 3 Somatuline Autogel (lanreotide acetate)
47 Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly Completed NCT00444873 Phase 3 lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
48 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
49 Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients Completed NCT00383708 Phase 3 lanreotide (Autogel formulation);Pegvisomant
50 Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly Completed NCT00372697 Phase 3 Octreotide acetate 30 mg suspension

Search NIH Clinical Center for Hyperpituitarism

Cochrane evidence based reviews: hyperpituitarism

Genetic Tests for Hyperpituitarism

Anatomical Context for Hyperpituitarism

MalaCards organs/tissues related to Hyperpituitarism:

42
Pituitary, Bone, Brain, Liver, Testes, Skeletal Muscle, Heart

Publications for Hyperpituitarism

Articles related to Hyperpituitarism:

# Title Authors Year
1
Hyperpituitarism ( 29489207 )
2018
2
Congenital hyperpituitarism of hypothalamic origin: a new diencephalic syndrome with endocrine manifestations. ( 14444640 )
1959
3
Psychological findings in a case of von Recklinghausen's disease and hyperpituitarism. ( 13367234 )
1956
4
Further evidence that hyperthyroidism (Graves' disease) is not hyperpituitarism: effects of triiodothyronine and sodium iodide. ( 14367487 )
1955
5
Graves' disease: hyperthyroidism or hyperpituitarism. ( 13022743 )
1952
6
Creatine-creatinine metabolism in adult and juvenile hyperpituitarism. ( 18877070 )
1948
7
Hyperpituitarism and Hypopituitarism. ( 19312151 )
1940
8
Thyrotoxicosis with Unilateral Exophthalmos, Hyperpituitarism, and Infantile Hemiplegia. ( 19990197 )
1935
9
Case of Hyperpituitarism. ( 19984234 )
1925

Variations for Hyperpituitarism

Expression for Hyperpituitarism

Search GEO for disease gene expression data for Hyperpituitarism.

Pathways for Hyperpituitarism

Pathways related to Hyperpituitarism according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.12 GH1 GHR GHRH IGF1 INS PRL
2
Show member pathways
12.55 GH1 GHR IGF1 INS PRL
3
Show member pathways
12.53 GH1 GHR IGF1 INS
4
Show member pathways
12.51 GH1 GHR GHRH POMC PRL SST
5
Show member pathways
11.72 GH1 IGF1 INS POMC
6 11.66 GH1 IGF1 INS
7 11.25 GH1 GHR IGF1
8 11.05 IGF1 INS
9
Show member pathways
10.91 POMC TRH
10
Show member pathways
10.74 GH1 GHR PRL

GO Terms for Hyperpituitarism

Cellular components related to Hyperpituitarism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 GH1 GHR GHRH IGF1 INS POMC
2 secretory granule GO:0030141 9.32 POMC TRH
3 extracellular region GO:0005576 9.28 GH1 GHR GHRH IGF1 INS POMC
4 growth hormone receptor complex GO:0070195 9.26 GH1 GHR
5 endosome lumen GO:0031904 9.13 GH1 INS PRL

Biological processes related to Hyperpituitarism according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.95 GHRH INS POMC SST SSTR2 TRH
2 positive regulation of cell proliferation GO:0008284 9.89 GHRH IGF1 INS PRL
3 cellular protein metabolic process GO:0044267 9.79 IGF1 INS PRL
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.7 GH1 GHR IGF1
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.67 GH1 IGF1 INS
6 cell-cell signaling GO:0007267 9.65 GHRH INS POMC SST TRH
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.63 GH1 GHR IGF1
8 activation of protein kinase B activity GO:0032148 9.61 IGF1 INS
9 positive regulation of glucose import GO:0046326 9.6 IGF1 INS
10 positive regulation of mitotic nuclear division GO:0045840 9.58 IGF1 INS
11 response to food GO:0032094 9.58 GHR GHRH
12 positive regulation of multicellular organism growth GO:0040018 9.58 GH1 GHR GHRH
13 positive regulation of glycolytic process GO:0045821 9.57 IGF1 INS
14 positive regulation of glycogen biosynthetic process GO:0045725 9.56 IGF1 INS
15 insulin-like growth factor receptor signaling pathway GO:0048009 9.55 GHR IGF1
16 growth hormone receptor signaling pathway GO:0060396 9.54 GH1 GHR
17 regulation of multicellular organism growth GO:0040014 9.54 GHR IGF1 PRL
18 negative regulation of feeding behavior GO:2000252 9.51 INS TRH
19 positive regulation of JAK-STAT cascade GO:0046427 9.5 GH1 GHR PRL
20 positive regulation of lactation GO:1903489 9.43 GHRH PRL
21 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.33 GH1 GHR PRL
22 regulation of signaling receptor activity GO:0010469 9.23 GH1 GHRH IGF1 INS POMC PRL
23 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.13 GH1 GHRH IGF1

Molecular functions related to Hyperpituitarism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin receptor binding GO:0005158 9.26 IGF1 INS
2 hormone activity GO:0005179 9.23 GH1 GHRH IGF1 INS POMC PRL
3 insulin-like growth factor receptor binding GO:0005159 9.16 IGF1 INS
4 prolactin receptor binding GO:0005148 8.96 GH1 PRL

Sources for Hyperpituitarism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....